Xencor

Xencor Current Liabilities

The Current Liabilities of Xencor (XNCR) as of Oct 10, 2026 is 92.32 M USD. In the previous year, Current Liabilities was 148.12 M USD — a change of -37.67% (lower).

Current Liabilities

92.32 MUSD

YoY

-37.67%

Last updated:

Current Liabilities of Xencor is 2025 92.32 M USD. Current Liabilities of Xencor was 2024 148.12 M USD. It decreases by -37.67% lower compared to the previous year.

The Xencor Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
33.14 M USD
Jan 1, 2019
32.55 M USD
Jan 1, 2020
47.95 M USD
Jan 1, 2021
86.81 M USD
Jan 1, 2022
56.92 M USD
Jan 1, 2023
101.96 M USD
Jan 1, 2024
148.12 M USD
Jan 1, 2025
92.32 M USD
The Xencor Current Liabilities history
YEARCurrent LiabilitiesYoY
92.32 MUSD-37.67%
148.12 MUSD+45.27%
101.96 MUSD+79.11%
56.92 MUSD-34.43%
86.81 MUSD+81.06%
47.95 MUSD+47.29%
32.55 MUSD-1.76%
33.14 MUSD-60.30%
83.47 MUSD+246.48%
24.09 MUSD+75.32%
13.74 MUSD+120.15%
6.24 MUSD+15.04%
5.43 MUSD-78.15%
24.83 MUSD+13.21%
21.93 MUSD—
Access this data via the Eulerpool API

Xencor Stock analysis

What does Xencor do? The company Xencor Inc was founded in 1997 and has since become a significant biotechnology company specializing in the development of therapeutic proteins. Xencor's goal is to develop innovative and tailored therapies for the treatment of serious diseases such as cancer and autoimmune diseases. The company is headquartered in Monrovia, California, and employs a growing number of scientists, engineers, and other professionals specialized in the development of new themes and products. Xencor has acquired a variety of patents over the years to protect its intellectual property. Its business model is based on the development of new therapeutics through its proprietary XmAb technology platform, which enables the production of highly specific polyclonal antibodies that can improve the efficiency and safety of disease treatments. Xencor has divided its business activities into various divisions, including the development of immuno-oncology products, autoimmune therapies, and new methods for the therapy of inflammatory bowel diseases. The company has developed a wide range of products, including a new class of therapeutic antibodies that mobilize and strengthen patients' own immune system to fight cancer cells. By combining these antibodies with other therapies, the effectiveness of the treatment can be further increased. In the autoimmune diseases division, Xencor has developed new therapeutics to better regulate patients' immune system and treat dangerous autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, or lupus. Another focus of the company is the development of therapies for inflammatory bowel diseases such as ulcerative colitis or Crohn's disease. By developing specific antibodies involved in the inflammatory processes in the intestine, Xencor can contribute to improving the treatment of these conditions. Xencor aims to accelerate the development of new therapeutics while improving their efficacy and safety. With the help of its proprietary XmAb technology platform, the company is able to develop new drugs faster and more effectively than conventional methods. Through the combination of technology, research and development, and a high level of commitment, Xencor pursues its vision and has successfully established itself as one of the leading companies in the biotechnology industry. Xencor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Xencor stock

Current Liabilities of Xencor is 92.32 M USD in 2025.

Current Liabilities of Xencor changed from 148.12 M USD to 92.32 M USD, representing a -37.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Xencor since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Xencor historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Xencor

All Key Metrics — Xencor